*ST海馬(000572.SZ):2019年業績扭虧為盈至8519.62萬元
格隆匯3月30日丨*ST海馬(000572.SZ)披露2019年年度報告,實現營業收入46.91億元,同比下降7.06%;歸屬於上市公司股東的淨利潤8519.62萬元,上年同期虧損16.37億元;歸屬於上市公司股東的扣除非經常性損益的淨虧損7.31億元;基本每股收益0.0518元。
報告期,公司鄭州基地新產品——海馬8S已於2019年7日8日正式上市,並開啟了互聯網直賣模式,新產品和新的營銷模式得到了市場和消費者的初步認可。受外部大環境、公司品類戰略實施和產品規劃的影響,公司銷量與多數同行業公司走勢基本一致,全年汽車銷量為2.95萬輛,同比大幅下滑,產銷量未達成年初目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.